🇺🇸 Macugen (Pegaptanib Sodium) in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 7

Most-reported reactions

1. Adhesion — 1 report (14.29%)
2. Cataract — 1 report (14.29%)
3. Diabetes Mellitus — 1 report (14.29%)
4. Drug Hypersensitivity — 1 report (14.29%)
5. Intermediate Uveitis — 1 report (14.29%)
6. Iridocyclitis — 1 report (14.29%)
7. Vitreous Detachment — 1 report (14.29%)

Source database →

Frequently asked questions

Is Macugen (Pegaptanib Sodium) approved in United States?

Macugen (Pegaptanib Sodium) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Macugen (Pegaptanib Sodium) in United States?

Retina Institute of Hawaii is the originator. The local marketing authorisation holder may differ — check the official source linked above.